A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Heo, Jeong | - |
dc.contributor.author | Park, Jun Yong | - |
dc.contributor.author | Lee, Heon Ju | - |
dc.contributor.author | Tak, Won Young | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Kim, Do Young | - |
dc.contributor.author | Yoon, Ki Tae | - |
dc.contributor.author | Park, Soo Young | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Han, Kwang-Hyub | - |
dc.contributor.author | Cho, Mong | - |
dc.contributor.author | Ahn, Sang Hoon | - |
dc.date.available | 2020-11-10T11:59:34Z | - |
dc.date.issued | 2012-08 | - |
dc.identifier.issn | 1359-6535 | - |
dc.identifier.issn | 2040-2058 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/30856 | - |
dc.description.abstract | Background: Growing numbers of chronic hepatitis B (CHB) patients in the Asia-Pacific region have failed first-line therapy with low genetic barrier drugs. This prospective, 96-week study investigated the antiviral efficacy, safety and tolerability of switching to entecavir versus maintaining lamivudine in CHB patients with a partial virological response to lamivudine. Methods: A total of 72 hepatitis B e antigen (HBeAg)-positive patients, with serum HBV DNA >= 60 IU/ml after >= 6 months lamivudine monotherapy were randomized 1:1 to receive either entecavir 1.0 mg/day, or continued lamivudine 100 mg/day. Results: Mean duration of prior lamivudine treatment was 15.1 months in the lamivudine-maintained patients and 16.1 months in the entecavir-switch patients, with mean baseline HBV DNA levels of 4.66 and 4.55 log(10) IU/ml, respectively. A greater proportion of entecavirswitch than lamivudine-maintained patients achieved undetectable HBV DNA at all time points (67.6% versus 11.4% at week 96; P<0.001). Entecavir-switch patients achieved a greater mean decrease in HBV DNA level by week 4, maintained through week 96. Entecavir-switch patients with baseline HBV DNA<5 log(10) IU/ml were more likely to achieve a virological response at week 96. A total of 6 (17.6%) entecavir-switch and 2 (5.7%) lamivudine-maintained patients achieved HBeAg loss, and 3 (8.8%) entecavir and 1 (2.9%) lamivudine patients achieved HBeAg seroconversion. Genotypic resistance to the assigned intervention emerged in 82.9% (29/35) of lamivudine-maintained patients, and in 3% (1/34) of entecavir-switch patients after 96 weeks. Conclusions: Switching to entecavir in patients with a partial virological response to lamivudine resulted in increased virological efficacy and lower rates of antiviral resistance than maintaining lamivudine. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | International Medical Press | - |
dc.title | A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.3851/IMP2277 | - |
dc.identifier.scopusid | 2-s2.0-84871894884 | - |
dc.identifier.wosid | 000208835300010 | - |
dc.identifier.bibliographicCitation | Antiviral Therapy, v.17, no.8, pp 1563 - 1570 | - |
dc.citation.title | Antiviral Therapy | - |
dc.citation.volume | 17 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1563 | - |
dc.citation.endPage | 1570 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | LONG-TERM LAMIVUDINE | - |
dc.subject.keywordPlus | VIRUS-INFECTION | - |
dc.subject.keywordPlus | GENOTYPE-C | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | HEALTH | - |
dc.subject.keywordPlus | SAFETY | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.